
Platform for the High Throughput Generation and Validation of Affinity ReagentsAward last edited on: 3/10/2025
Sponsored Program
SBIRAwarding Agency
NIH : NIGMSTotal Award Amount
$2,160,481Award Phase
2Solicitation Topic Code
859Principal Investigator
Michael P WeinerCompany Information
Abbratech Inc
25 Business Park Drive Suite C
Branford, CT 06405
Branford, CT 06405
(203) 606-5394 |
admin@abbratech.com |
www.abbratech.com |
Location: Single
Congr. District: 03
County: New Haven
Congr. District: 03
County: New Haven
Phase I
Contract Number: N/AStart Date: 2/1/2023 Completed: 1/31/2025
Phase I year
2023Phase I Amount
$1Phase II
Contract Number: 1R44GM148998-01Start Date: 2/1/2023 Completed: 1/31/2025
Phase II year
2023(last award dollars: 2024)
Phase II Amount
$2,160,480Public Health Relevance Statement:
NARRATIVE Improved methods for deriving high quality affinity reagents will be needed to keep up with the pending impact when single molecule protein sequencing instrumentation comes "online' in the next few years. When that time comes, it is not a realistic expectation to be able to go to an existing Ab catalog for mAbs that are well-validated, cloned, and sequenced, and that work in specific applications against newly discovered biomarkers. The high costs and low throughput of current antibody-generating technologies represent significant roadblocks to the development of a comprehensive and broadly available resource of renewable affinity reagents. Thus, there is an urgent need for all Abs to be defined by their sequences and made recombinant. Terms: